-- Christian Behrenbruch, Managing Director and Group Chief Executive Officer, on April 28, 2026, executed a purchase for 67,935 shares in Telix Pharmaceuticals (TLX) for $996,738. Following the Form 4 filing with the SEC, Behrenbruch has control over a total of 20,742,935 ordinary shares of the company, with 20,742,935 controlled indirectly.
SEC Filing: